NanoString Technologies

NanoString Technologies, Inc. engages in the development and commercialization of instruments and services for profiling of genes and proteins from tissue sample. It offers the GeoMx Digital Spatial Profiler, nCounter Analysis System product platforms, GeoMx Assays, nCounter Panels & Assays and CosMx Spatial Molecular. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June, 2003 and is headquartered in Seattle, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

NanoString Technologies reports robust Q4 revenue and optimistic 2023 outlook

NanoString Technologies showcased strong Q4 2022 performance with revenue exceeding guidance and a positive outlook for 2023.
While facing challenges such as expected EBITDA losses and nCounter revenue decline, NanoString is leveraging opportunities in spatial biology and customer synergies.
The company's strengths lie in market-leading technology, positive customer feedback on CosMx instruments, and a cash-generating nCounter business.
Overall, NanoString's strategic focus on spatial biology and operational improvements position it for continued growth and innovation.

NanoString Technologies surpasses Q1 revenue targets, CosMx shines

NanoString Technologies had a strong Q1 2023, exceeding revenue guidance and raising full-year expectations.
Positive customer feedback and competitive positioning of CosMx in the spatial imager category are key strengths.
Challenges include EBITDA loss, capacity constraints, and shifts in product demand.
Opportunities lie in achieving cash flow breakeven, product growth, and market dominance with CosMx.

NanoString Technologies reports record Q2 revenue and strategic growth plans

NanoString Technologies delivered strong Q2 results, exceeding revenue guidance and showcasing growth in spatial biology.
The company's strategic objectives for 2023 focus on market expansion and product innovation, supported by a commitment to operational efficiency.
While facing challenges such as ongoing litigation and financial discussions, NanoString remains optimistic about its growth prospects and balance sheet strengthening.

NanoString Technologies achieves record revenue, eyes growth opportunities in 2024

NanoString Technologies reported strong revenue growth and cost reduction in Q3 2023.
Focus on spatial biology market penetration and new product offerings to drive future growth.
Legal challenges in Europe and backlog delays pose challenges to be addressed.
Improved gross margins and lower expenses expected to enhance profitability by 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

SEATTLE--(BUSINESS WIRE)-- #spatialbiology--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a peer-reviewed paper published in Nature Genetics using the GeoMx Human Whole Transcriptome Atlas (WTA) to construct a high-resolution molecular landscape of pancreatic cancer. This paper, along with a tissue image generated using the GeoMx® Digital Spatial Profiler (DSP), is featured on the cover of the August 2022 edition o

Study Using NanoString's GeoMx Digital Spatial Profiler Featured on the Cover of Nature Genetics

The consensus price target hints at an 116.4% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think NanoString (NSTG) Could Surge 116%: Read This Before Placing a Bet

NanoString Technologies, Inc. (NASDAQ:NSTG ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Doug Farrell - Vice President, Investor Relations Brad Gray - President and Chief Executive Officer Tom Bailey - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Dan Brennan - Cowen Edmund Debler - Morgan Stanley Dan Arias - Stifel Operator Hello and welcome to the NanoString Second Quarter Operating Results. My name is Katie, and I'll be coordinating your call today.

NanoString Technologies, Inc.'s (NSTG) CEO Brad Gray on Q2 2022 Earnings Call Transcript

NanoString (NSTG) delivered earnings and revenue surprises of -37.10% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NanoString Technologies (NSTG) Reports Q2 Loss, Lags Revenue Estimates

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2022. Second Quarter Financial Highlights Product and service revenue of $32.0 million GeoMx® Digital Spatial Profiler (DSP) revenue of $10.9 million. GeoMx DSP revenue includes: Instrument revenue of $5.2 million Consumables revenue of $5.7 million, annualized pull-through

NanoString Technologies Releases Operating Results for Second Quarter of 2022

NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: NanoString Technologies (NSTG) Q2 Earnings Expected to Decline

The consensus price target hints at a 171.7% upside potential for NanoString (NSTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 172% Upside in NanoString (NSTG): Can the Stock Really Move This High?

NanoString (NSTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NanoString (NSTG) Surges 5.1%: Is This an Indication of Further Gains?

SEATTLE--(BUSINESS WIRE)-- #earnings--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report second quarter 2022 operating results after the close of the market on Thursday, August 4, 2022. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update. Investors and other interested parties should register for the conference cal

NanoString to Release Second Quarter 2022 Operating Results and Host Conference Call on Thursday, August 4, 2022

SEATTLE--(BUSINESS WIRE)-- #spatialbiology--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced today the commercial unveiling of its new AtoMx™ Spatial Informatics Portal (SIP) at the Spatial Multiomic Symposium at the 2022 AGBT General Meeting in Orlando, FL. Attendees of the conference will have a chance to preview AtoMx SIP at the symposium on Monday, June 6, 2022, from noon to 4:00 pm EDT. The event will be live-streamed

NanoString Unveils AtoMx Spatial Informatics Portal at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced plans to commercially unveil the CosMx™ Spatial Molecular Imager (SMI) and its new spatial informatics portal during a Spatial Multiomic Symposium, which will be held on Monday, June 6 from noon to 4:00 pm EDT. The event will be live-streamed and held in person, and details can be found here: Spatial Multiomics Symposium - Nan

NanoString to Unveil New Platforms and Showcase Spatial Biology Research at 2022 Advances in Genome Biology and Technology (AGBT) General Meeting

SEATTLE--(BUSINESS WIRE)-- #spatialbiology--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a seamless, cloud-based workflow that improves the spatial data analysis experience of customers using Illumina NextSeq™ 1000 and NextSeq™ 2000 sequencing systems and the GeoMx® Digital Spatial Profiler. The spatial analysis of whole transcriptomes combined with proteome analytes can now be simplified using this integrated, pu

NanoString Launches Integrated Informatics to Facilitate Spatial Biology Research Using Next Generation Sequencing

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 2022 UBS Global Healthcare Conference. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, May 25, 2022, at 9:15 am ET. Interested parties can access the live webcast with accompanying slides from the investor section of

NanoString to Webcast Presentation from the UBS 2022 Global Healthcare Conference

NanoString Technologies, Inc. Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Doug Farrell - VP of IR & Corporate Communications Brad Gray - CEO, President & Director Tom Bailey - CFO Conference Call Participants Daniel Brennan - Cowen Dan Arias - Stifel Julia Qin - JPMorgan Kyle Mikson - Canaccord Genuity Catherine Schulte - Robert W. Baird Tejas Savant - Morgan Stanley Operator Hello.

NanoString Technologies, Inc. (NSTG) CEO Brad Gray on Q1 2022 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the first quarter ended March 31, 2022. First Quarter Financial Highlights Product and service revenue of $30.8 million GeoMx® Digital Spatial Profiler (DSP) revenue of $9.7 million. GeoMx DSP revenue includes: Instrument revenue of $4.8 million, 31% year-over-year decline Consumables revenue of $4.9 millio

NanoString Technologies Releases Operating Results for First Quarter of 2022

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report first quarter 2022 operating results after the close of the market on Tuesday, May 10, 2022. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update. Investors and other interested parties should register for the conference call in

NanoString to Release First Quarter 2022 Operating Results and Host Conference Call on Tuesday, May 10, 2022

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of Dr. Teresa (Teri) Foy to the Board of Directors, effective April 18, 2022. “I am honored to welcome Dr. Foy to the team. Teri is a leader in immuno-oncology and cellular therapy, with decades of experience in pharmaceutical research,” said president and chief executive officer Brad Gray. “Immunology and onco

NanoString Appoints Dr. Teresa Foy to Board of Directors

Shares of NanoString Technologies Inc. ntsg plunged 32.8% toward a two-year low in morning trading Wednesday, enough to make them the biggest losers trading on major U.S. exchanges, after the provider of life science discovery tools warned about a revenue miss, citing execution missteps. The company said late Tuesday that it now expects first-quarter product and service revenue of $31 million, below the previously provided guidance range of $34 million to $38 million.

NanoString stock plunges after revenue warning, but analyst says selloff appears 'way overdone'

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced preliminary total product and service revenue of approximately $31 million for the first quarter. This unaudited estimate, based on management's preliminary financial analysis, is lower than the company's previous guidance for product and service revenue of $34 million to $38 million for the first quarter of 2022. Preliminary F

NanoString Technologies Announces Preliminary Revenue for First Quarter of Fiscal Year 2022

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of over 125 studies enabled by NanoString platforms that will be presented at the 2022 meeting of the American Association of Cancer Research (AACR), which will be held April 8-13, 2022. At AACR 2022, over 110 posters and 15 oral presentations will showcase unique biological insights generated using NanoString T

NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference

SEATTLE--(BUSINESS WIRE)--Today, NanoString announced the commercial unveiling of the nCounter® Pro Analysis System, the next generation of the nCounter instrument platform.

NanoString Launches New nCounter Pro Analysis System

The mean of analysts' price targets for NanoString (NSTG) points to an 116.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does NanoString (NSTG) Have the Potential to Rally 117% as Wall Street Analysts Expect?

The mean of analysts' price targets for NanoString (NSTG) points to a 121.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in NanoString (NSTG)? Wall Street Analysts Think 122%

The average of price targets set by Wall Street analysts indicates a potential upside of 103.7% in NanoString (NSTG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does NanoString (NSTG) Have the Potential to Rally 104% as Wall Street Analysts Expect?

NanoString Technologies' (NSTG) CEO Brad Gray on Q4 2021 Earnings Call Transcript

News for NanoString Technologies Stock (NSTG)